42 participants
HAIC, Lenvatinib, and Cadonilimab as Conversion Therapy for Initially Unresectable Hepatocellular Carcinoma
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2026-05-22
- Start Date:
- 2023-12-07
- Completion:
- 2026-06-30
Conditions
- Hepatocellular Carcinoma Non-resectable
Interventions
- PROCEDURE
- DRUG
No Results Yet